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Welcome to the inaugural issue of the Journal of Renal and
Hepatic Disorders. The aim of the journal is to promote the
study and dissemination of research involving both renal
and hepatic organ systems and their impact on the whole
organism in both healthy and diseased states. In addition,
the focus of the journal will provide a unique forum in
which the interdependence and interactions between the
liver and kidney will be of particular interest.
Although there seems to be a proliferation of open journals
in the medical arena, our editorial board feels that the study
of the interdependence of organ systems is underrepresented.
Those of us in the ﬁeld of transplantation have an intuitive
understanding of the interrelationship between organ sys-
tems, given our exposure to patients with dual organ failure.
When a single organ system fails, the impact is felt through-
out several systems in a cascade of effects that may or may
not be reversible once the primary organ failure has been
reversed. A common and well-known example of this interac-
tion is the hepatorenal syndrome in end-stage cirrhosis of the
liver in which the vasogenic effects of liver disease initially
result in acute kidney injury but may progress to irreversible
ischemic renal failure if the vasogenic inﬂuence of liver failure
is not reversed quickly enough (1–3). The increasing impor-
tance of this phenomenon is evidenced by the proliferation
of simultaneous liver/kidney transplantation over the last dec-
ade (4, 5).
Although the pathogenesis and reversal of the hepatorenal
syndrome is an excellent example of the area of focus for the
journal, the aims of the journal are wider in scope than end-
stage disease and transplantation alone. As the kidney and
liver are two of the most metabolically inﬂuential organs in
the body, the potential for the study of physiological and/or
pathophysiologic interactions is unlimited. A PubMed search
using the title keywords “Kidney” and “Liver” for the year
2015 returned 250 titles widely ranging from exercise phy-
siology to the impact of hepatitis B and C in renal transplant
recipients (6, 7). Other sampled articles involved markers of
co-toxicities, and micro-RNA proﬁles involving both organ
systems were described due to acetaminophen overdose (8).
The emerging pathophysiology of fatty liver disease is a
growing topic (9).
The interdependence of homeostatic mechanisms originat-
ing from the combined effects of the liver and kidney in main-
taining nitrogen balance is exempliﬁed in the recent articles
with novel transporter mutations (10, 11).
Furthermore, the impact of inherited disorders such as
polycystic disease or nitrogen metabolism may be a fruitful
area for further discovery (12).
The editorial board of the Journal of Renal and Hepatic
Disorders aims to promote the greater understanding and dis-
semination of original works in all areas involving the inter-
play of these two organ systems, both in the basic scientiﬁc
and clinical realms. Toward this aim, original articles, com-
prehensive reviews, case reports, short communications,
and letters to the editor on any aspects of kidneys and liver
are suitable for submission. All submitted manuscripts will
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undergo a rigorous peer review and will be published in an
open access manner for the widest potential dissemination.
Our goal is to achieve widespread indexing and continued
growth and to increase the prestige of the journal in the scien-
tiﬁc community. We look forward to a rewarding and scien-
tiﬁcally productive relationship with our community and
contributors.
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